Glauconix enables pharmaceutical companies to bring ophthalmic drugs to market faster and cheaper.
Glauconix™ is the leading developer of ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and drug discovery. Initially Glauconix™ has focused in the ocular field on the need for new tissue models for development novel glaucoma therapeutics with the creation of nine tissue platforms. Glaucoma, the leading cause of irreversible blindness, is currently reaching epidemic proportions - 20% of the population aged 50+ will be affected. Given the limitations of current approaches, e.g. patient compliance challenges, varying benefits across divergent populations, and incomplete efficacy across different disease etiologies, there is a strong need for new innovative treatments.
The growing field of human tissue platforms will accelerate therapeutic innovation in many fields. They provide species-relevant models that integrate human genetics, and more closely resemble actual human physiology to enable rapid testing and discovery across diverse population genetics. These models can save R&D time, resources, and lead to more impactful outcomes with significant insight earlier in the process.
Our models have been used from early target identification through clinical mechanism-of-action and dose optimization. Our capabilities include:
• Gene Target Screening
• Molecule Screening
• Genetic / Population Screening
• Safety / Toxicity
• Mechanism of Action
• Dose Range & Efficacy
• Lead Optimization
Glauconix was founded in 2014 by Dr. Karen Torrejon. As a PhD candidate at SUNY Polytechnic Institute's College of Nanoscale Science & Engineering Dr. Torrejon discovered an unmet need for realistic ex-vivo ocular tissue models. Dr. Torrejon learned that many glaucoma drugs were failing in clinical trials because researchers did not have a realistic or reliable method for testing drug efficacy, and as a result drug companies were wasting millions of dollars and years of research time.
After learning about this issue, Dr. Torrejon focused her PhD research on developing a solution, and in addition to receiving her PhD, she developed a technology that provided a reliable and realistic process for identifying effective glaucoma drugs.
Since receiving her PhD the technology has improved and evolved enabling Glauconix to provide a suite of services that are sure to save time and money for pharmaceutical companies developing ocular drugs.